Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Conditions
Prostate CancerSummary
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).
Detailed Description
The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Central Contacts
- Astellas Pharma Global Development, Inc.
- 800-888-7704
- [email protected]
Study Director
- Medical Director
Eligibility Criteria
Inclusion Criteria:
Physician inclusion criteria
* The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
* The physician has cared for at least ten nmHSPC patients in the past year.
* The physician has experience prescribing NHT and ADT. Patient inclusion criteria
* The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.
Exclusion Criteria:
Physician exclusion criteria
* None Patient exclusion criteria
* The patient is castration resistant.
* The patient has metastatic PC.
Study Plan
Participants
Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.
OTHER:
No InterventionDescription:
No investigational drug will be administered to participants in this study.
Outcome Measures
Primary Outcome Measures
Patients' Preference weights for different treatment attributes
Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)
Timeline
Last Updated
February 14, 2025Start Date
July 15, 2024Today
May 10, 2025Completion Date ( Estimated )
February 28, 2025
Sponsors of this trial
Lead Sponsor
Astellas Pharma Global Development, Inc.